Neovae Biosciences

Oral, minimally systemically absorbed antibiotic formulation indicated for SIBO, IBS‑D and reduction in recurrence risk of hepatic encephalopathy.

Oral agent indicated to lower high serum phosphate levels in patients with kidney disease, including those on dialysis.

Orally active synthetic vitamin D analog for management of secondary hyperparathyroidism with lower calcemic and phosphatemic effects versus calcitriol.

Extended‑release oral formulation of an opioid analgesic intended for around‑the‑clock management of severe, chronic pain not controlled by other analgesics.

Oral antidiabetic formulations including a DPP‑4 inhibitor and a combination product with metformin for glycemic control in type 2 diabetes.

Oral capsule containing probiotics and prebiotics intended to support digestion, reduce bloating and modulate gut microbiota.

Oral antibiotic formulation intended for treatment of respiratory and urinary tract infections and selected skin and gynecological infections.

Oral antidiabetic agent described as lowering blood glucose by increasing urinary glucose excretion, with suggested benefits for kidney disease and heart failure outcomes.